Atara Biotherapeutics
ATRA
139 hedge funds and large institutions have $1.5B invested in Atara Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 15 closing their positions.
287% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $261K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 47
0.07% more ownership
Funds ownership: 4.23% → 4.31% (+0.07%)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 140 → 139 (-1)
7% less capital invested
Capital invested by funds: $1.61B → $1.5B (-$106M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.7M |
| 2 |
EC
Eminence Capital
New York
|
+$19.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$19M |
| 4 |
Citigroup
New York
|
+$12.5M |
| 5 |
N
Natixis
Paris,
France
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$14.9M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$13.5M |
| 3 |
JP Morgan Chase
New York
|
-$10.1M |
| 4 |
LPC
Lion Point Capital
New York
|
-$6.27M |
| 5 |
Two Sigma Advisers
New York
|
-$5.51M |
ATRA Hedge Fund Activity: Q4 2021 in Review
139 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2021, worth a combined $1.5B — down 6.6% from $1.61B a quarter earlier.
Fund positioning in ATRA was balanced in Q4 2021: 15 funds opened new positions, 15 closed out, 51 added to existing stakes and 47 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $38.7M. The largest seller was Wasatch Advisors, cutting an estimated $14.9M.
- 139 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2021, down from 140 in Q3 2021.
- Funds reported $1.5B of Atara Biotherapeutics stock for Q4 2021, down 6.6% quarter-over-quarter.
- 15 funds opened new Atara Biotherapeutics positions in Q4 2021 and 15 closed out, a net change of 0 holders.
- The largest Atara Biotherapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $38.7M added.
- The largest Atara Biotherapeutics seller in Q4 2021 was Wasatch Advisors, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2021.